Sorafenib in adjuvant setting: call for precise and personalized therapy

Wei Zhang¹

Affiliations

¹ Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

Comment

Wei Zhang. Transl Gastroenterol Hepatol. 2016.

. 2016 Mar 16:1:13.

doi: 10.21037/tgh.2016.03.13. eCollection 2016.

Wei Zhang¹

¹ Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

No abstract available

Conflict of interest statement

The author has no conflicts of interest to declare.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Bruix J, et al. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361969 Clinical Trial.

1. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54. 10.1016/S1470-2045(15)00198-9 - DOI - PubMed
1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed
1. Lencioni R, Llovet JM, Han G, et al. Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC: Phase II, Randomized, Double-Blind SPACE Trial. J Hepatol 2016. Doi: 10.1016/j.jhep.2016.01.012 - DOI - PubMed
1. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-27. 10.1016/j.ejca.2011.05.007 - DOI - PubMed
1. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 2014;141:117-24. 10.1016/j.pharmthera.2013.09.003 - DOI - PubMed